Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt small index

ARDS: early-phase trial registry

10 of 15 indexed ARDS trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,140 of 28,707 conditions by registered trial count.

15 US clinical trials · 10 currently recruiting · #1,140 of 28,707 conditions by registered trial count

ARDS: 15 US clinical trials tracked, 10 recruiting.

ARDS is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is PPD Development, running 4 of these trials.

Enrollment posture brief

Registry condition ards

OPEN 10 | RECR 67% | LATE 1 | EARLY 6 | RANK #1140 | SPON 4

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

ARDS (this)67%Advanced Lung Non-Small Cell53.3%AIDS26.7%Adult Acute Myeloid Leukemia0%Adult Glioblastoma0%
Open-enrollment share among volume-matched conditions near ARDS

ARDS lists 10 open slots (67% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for ARDS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. ARDS is recruiting above its size-band peers.

    10 of 15 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates ARDS research.

    PPD Development accounts for 4 of 15 trials (26.7%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical ARDS enrolment sits around 200 participants.

    Median target enrolment is 200 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.

  4. ARDS research is mostly interventional.

    12 interventional and 3 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

15 total, page 1 of 1

RECRUITING 4,000 participants

The APS Phenotyping Study

Vanderbilt University Medical Center

NCT06521502

RECRUITING Phase 3 970 participants

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Direct Biologics

NCT05354141

RECRUITING NA 800 participants

Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.

The University of Texas Medical Branch, Galveston

NCT06737432

RECRUITING NA 740 participants

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

Unity Health Toronto

NCT03963622

RECRUITING Phase 2 600 participants

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

PPD Development

NCT06703073

RECRUITING Phase 2 200 participants

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

PPD Development

NCT06701656

RECRUITING Phase 2 200 participants

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

PPD Development

NCT06701682

RECRUITING Phase 2 200 participants

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

PPD Development

NCT06701669

RECRUITING NA 180 participants

Clinical Decision Support Tool in PARDS Pilot Study

Children's Hospital Los Angeles

NCT04068012

RECRUITING 50 participants

Ventilatory Parameters in Predicting Outcomes in ARDS Patients

CentraCare

NCT06400095

COMPLETED 89 participants

Retrospective Postoperative ARDS Study at Vanderbilt University

Vanderbilt University

NCT00656071

COMPLETED Phase 1 72 participants

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Apellis Pharmaceuticals

NCT04402060

COMPLETED NA 58 participants

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

University of Vermont

NCT04067622

COMPLETED Phase 1 45 participants

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Cellenkos

NCT04468971

COMPLETED NA 13 participants

Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS

Christiana Care Health Services

NCT01272882

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on ARDS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cohort C: bevacizumab Drug
2 trials
Cohort B: placebo Drug
2 trials
Cohort B: paridiprubart Drug
2 trials
Cohort A: placebo Drug
2 trials
Cohort A: vilobelimab Drug
2 trials
APL-9 Drug
1 trials
Electrical Impedance Tomography monitoring Device
1 trials
CK0802 Biological
1 trials

US sites by state

Facility locations filed on ARDS trials. A trial with sites in several states counts in each.

New York 8 trials
California 8 trials
Michigan 7 trials
Illinois 7 trials
Minnesota 6 trials
Florida 6 trials
New Jersey 5 trials
Massachusetts 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this ARDS page

15 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ARDS condition card totals 15 registered trials; most-linked intervention Cohort C: bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.